Synthesis, Evaluation of Anti-Toxoplasma gondii Activity in vitro and Molecular Docking of Dihydroartemisinin Derivatives
作者:Hao Deng、Zheng-Ai Chen、Yin-Sheng Quan、Qing-Kun Shen、Zhe-Shan Quan
DOI:10.1007/s11094-021-02529-3
日期:2022.1
In this work, 21 dihydroartemisinin derivatives were synthesized, their chemical structures were characterized by 1H NMR, 13H NMR and high-resolution MS techniques, and anti-Toxoplasma gondii activity in vitro was evaluated using thiazole blue (MTT) assay. The selectivity index of compound (3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9-trime-thyldeca-hydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl 4-oxo-4-(pyridin-4-ylamino)butanoate (E2) was 2.24, which showed the strongest anti-T. gondii activity. In addition, the results of molecular docking studies show that E2 can be a better inhibitor of T. gondii calcium-dependent protein kinase 1 (TgCDPK1). Therefore, compound E2 has good potential as a drug for T. gondii treatment, and further research is needed to clarify its mechanism of action.
在这项工作中,合成了21种二氢青蒿素衍生物,采用1H NMR、13C NMR和高分辨率MS技术对其化学结构进行了表征,并使用噻唑蓝(MTT)法评估了其体外抗弓形虫活性。化合物(3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9-三甲基脱氢-12H-3,12-环氧[1,2]二氧披那[4,3-i]异喹啉-10-基4-酮-4-(吡啶-4-氨基)丁酸酯(E2)的选择性指数为2.24,显示出最强的抗弓形虫活性。此外,分子对接研究的结果表明,E2可能是T. gondii钙依赖性蛋白激酶1(TgCDPK1)更好的抑制剂。因此,化合物E2作为弓形虫治疗药物具有良好的潜力,但仍需进一步研究以阐明其作用机制。